No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Instruments & Supplies
Globally, SCHOTT Pharma AG & Co. KGaA specializes in the development, manufacturing, and distribution of sophisticated containment and delivery systems specifically designed for injectable pharmaceuticals, catering to the needs of the pharmaceutical and biotechnology sectors. Their comprehensive product portfolio encompasses both polymer and glass options across various crucial categories, including syringes, ampoules, vials, and cartridges. Their extensive range of syringes features specialized solutions such as the syriQ series (including BioPure for biologics and silicone-free variants) crafted from glass, ideal for vaccines and sensitive biologics, alongside the versatile polymer-based SCHOTT TOPPAC line, tailored for applications from cosmetic treatments and deep-cold storage to infusion therapy and delicate drugs. For cartridges, SCHOTT Pharma provides the cartriQ pharmaceutical glass series, designed for peptide, protein, and large-volume injectables, as well as double-chamber options for lyophilized drugs and break-resistant variants, supplemented by their TopLine and StandardLine offerings. Vial solutions include the adaptiQ pharmaceutical glass vial for general injectables, the EVERIC range focused on drug stability (pure, care for pH, strong & smooth for filling lines), SCHOTT Type I plus for specific formulations, and TopLyo to prevent fogging in lyophilized drugs, alongside their TopLine and StandardLine vials. The ampoule selection features easyOPC for convenient opening, Anti-Counterfeiting ampoules for enhanced security, and their dependable StandardLine options. Established in 1884 and based in Mainz, Germany, SCHOTT Pharma AG & Co. KGaA functions as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
www.schott.comNo one on the platform currently holds 1SXP.F.
No tracked institution reports a position in 1SXP.F as of their last filing.
No one on the platform has traded 1SXP.F yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 14.4% | 19.6% | — | — | — | |
| Rev. Growth % | 3.0% | 11.0% | ||||
| Profit Margin % | 14.9% | 15.6% | ||||
| Free Cash Flow Margin % | 3.6% | 4.3% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.0B | +5.0% | $0.98 | $0.95–$1.06 | — | 10 |
| 2027 | $1.1B | +6.4% | $1.09 | $1.03–$1.16 | — | 11 |
| 2028 | $1.2B | +6.8% | $1.23 | $1.10–$1.35 | — | 9 |
| 2029 | $1.2B | +6.0% | $1.32 | $1.28–$1.36 | — | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $0.26 | $0.25 | -4.1% |
| 2026-05-13 | $0.21 | $0.21 | +2.3% |
| 2026-02-11 | $0.18 | $0.22 | +24.4% |
| 2025-12-11 | $0.24 | $0.22 | -8.3% |
| 2025-08-12 | $0.30 | $0.31 | +3.3% |
| 2025-05-15 | $0.23 | $0.25 | +7.9% |
| 2025-02-13 | $0.20 | $0.19 | -2.6% |
| 2024-12-12 | $0.26 |
| $0.24 |
| -5.8% |
| +0.40% |
| $4.0B |
| — |
| DMP.DEDermapharm Holding SE | $37.90 | +1.34% | $1.9B | — |
| DRW3.DEDrägerwerk AG & Co. KGaA | $112.40 | +0.72% | $2.1B | — |
Source: Financial Modeling Prep · peers by sector/industry